Kardigan Acquires Prolaio to Build Innovative Heart Health Platform Kardigan, a heart health company focused on modernizing cardiovascular (CV) drug development, has announced its acquisition of Prolaio, a clinical intelligence company dedicated to advancing cardiology research and care through real-world…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural history of knee osteoarthritis, has received authorization from Health Canada to initiate the…
Savara Secures Up to $200 Million in Non-Dilutive Debt Financing from Hercules Capital Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, has announced a significant financial agreement with Hercules Capital, Inc. (NYSE: HTGC).…
Viz.ai AI-Powered Solution Identifies Hypertrophic Cardiomyopathy Earlier, Enhancing Clinical Care Viz.ai, a leading company in AI-powered disease detection and intelligent care coordination, has announced compelling new clinical data demonstrating the effectiveness of its Viz HCM module in detecting hypertrophic cardiomyopathy…
Coya Therapeutics Advances Treg-Derived Exosome Program Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function, has provided a comprehensive update on its investigational regulatory T cell-derived exosome…
Global Pharma Leader Adopts ValGenesis iClean for Digital Cleaning Validation ValGenesis, Inc., a global leader in digital validation lifecycle management solutions, has announced a significant milestone in its collaboration with a major pharmaceutical and biotechnology company. This industry giant has…
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate The global oligonucleotide synthesis market is poised for significant growth, expanding from USD 4.8 billion in the current year to an estimated USD 13.5 billion by 2035, reflecting a…
Quince Therapeutics Shares Business Update & 2024 Financial Results Quince Therapeutics, Inc., a late-stage biotechnology company focused on leveraging a patient’s own biology to treat rare diseases, has provided an update on its development pipeline and released financial results for…
IFF Pharma Showcases Next-Gen Excipients at CPHI Japan 2025 IFF Pharma Solutions is set to showcase its latest cutting-edge excipient technologies at CPHI Japan 2025, reinforcing its commitment to revolutionizing drug formulation and patient-centered pharmaceutical innovations. The event will take…
Johnson & Johnson to Build Advanced Biologics Facility in North Carolina Johnson & Johnson (the “Company”) is set to break ground on a new, cutting-edge biologics manufacturing facility in Wilson, North Carolina. The 500,000-square-foot facility represents a significant expansion of…
Pint Pharma Secures ANVISA Approval for BESREMi® in PV Treatment Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). This milestone marks…
GRM Information Management to Exhibit at USCAP Annual Meeting GRM Information Management (GRM) is set to showcase its specialized pathology storage services at the prestigious United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place from March 22-27…